We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca said it is “exploring options” with German manufacturer IDT Biologika to boost the supply of its vaccine in Europe during the second quarter of the year. Read More
A Government Accountability Office (GAO) review of COVID-19 vaccine development efforts found that vaccine producers are facing significant manufacturing hurdles as they scale up operations. Read More
The U.S. government has purchased 100 million additional doses of both the Pfizer/BioNTech and Moderna messenger RNA (mRNA)-based COVID-19 vaccines in an effort by the Biden administration to ramp up inoculations. Read More
Pharma giants Teva Pharmaceuticals and Merck are currently in talks about adding their significant manufacturing capabilities to COVID-19 vaccine production, though specifics have not been disclosed at this point. Read More
Pfizer said it can cut the time it takes to manufacture its COVID-19 vaccine by almost half from 110 days to an estimated 60 days, a change that should significantly increase the speed of U.S. vaccinations. Read More
GlaxoSmithKline previously announced it would delay a phase 2b trial of its adjuvanted vaccine candidate developed with Sanofi following lackluster results. Read More
Jazz Pharmaceuticals is set to acquire GW Pharmaceuticals, a UK drugmaker known for its CBD products Epidiolex (cannabidiol) and Sativex (nabiximols), for a whopping $7.2 billion. Read More